{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-007127","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.349313+00:00","generated_at":"2026-06-18T08:06:46.766575+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lineage Cell Therapeutics Q4 net loss $6.4M, revenue $1.9M; cash $57.9M; pipeline advances","bullets":["Q4 2022 net loss $6.4M ($0.03/sh), revenue $1.9M; FY2022 net loss $26.3M ($0.15/sh), revenue $14.7M.","Cash and securities $57.9M at Dec 31, 2022; expected to fund planned operations into Q3 2024.","Genentech initiated Phase 2a study of RG6501 (OpRegen) for geographic atrophy; RMAT and pre-IND submitted for OPC1 and VAC2.","Launched two new cell therapy programs for hearing/vision loss; appointed Jill Howe as CFO in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-007127","json":"https://secwatch.observer/filing/0001493152-23-007127.json","markdown":"https://secwatch.observer/filing/0001493152-23-007127.md","text":"https://secwatch.observer/filing/0001493152-23-007127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315223007127/0001493152-23-007127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315223007127/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:06:46.766575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ccb41e1ed79686e66c5302e1c7aee9b709f2cf68","claim":"Lineage Cell Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2022, a copy of which is furnished as Exhibit 99.1.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223007127/0001493152-23-007127-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}